Get the Stockscreener App
8.31
0.71%
-0.10
Omeros Corporation stock is traded at $8.31, with a volume of 141.55K.
It is down -0.71% in the last 24 hours and down -0.95% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$8.41
Open:
$8.4
24h Volume:
141.55K
Relative Volume:
0.18
Market Cap:
$479.82M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-4.4202
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-3.80%
1M Performance:
-0.95%
6M Performance:
+110.33%
1Y Performance:
+74.69%
1-Day Range:
$8.10
$8.625
1-Week Range:
$8.10
$9.10
52-Week Range:
$2.612
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
8.31 | 479.82M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.80 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.68 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.52 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.32 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Investor Network: Omeros Corporation to Host Earnings Call - ACCESS Newswire
Blue Trust Inc. Sells 1,910 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Loss-Making Omeros Corporation (NASDAQ:OMER) Expected To Breakeven In The Medium-Term - Simply Wall St
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us (OMER) - Seeking Alpha
Trading (OMER) With Integrated Risk Controls - Stock Traders Daily
Omeros Corporation Announces Statistical Analysis Results for Expanded Access ProgramSeattle, Washington–(BUSINESS WIRE)–Feb 20, 2025–Omeros Corporation (NASDAQ: OMER) announced today the statistical analysis results related to the expande - Defense World
Omeros announces results for narsoplimab expanded access program - Yahoo Finance
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA - Business Wire
Can This Drug Cut Death Risk by 66% in Transplant Patients? New Data Reveals Breakthrough - StockTitan
Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50 - MarketBeat
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings - Business Wire
Breakthrough TA-TMA Treatment Data: Narsoplimab Shows Promising Results in 128-Patient Study - StockTitan
Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program - BioSpace
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes Of Narsoplimab Treatment For Ta-Tma - Marketscreener.com
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company - Yahoo Finance
SG Americas Securities LLC Has $241,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Navigating OMER Stock: Omeros Corporation Journey - The InvestChronicle
Stordahl Capital Management Inc. Purchases New Shares in Omeros Co. (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Trading Up 5.3%Here's What Happened - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Down 4.4%Here's Why - MarketBeat
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Cantor Fitzgerald Forecasts Omeros FY2025 Earnings - Defense World
Omeros (NASDAQ:OMER) Shares Gap DownTime to Sell? - MarketBeat
Cantor Fitzgerald Comments on Omeros FY2025 Earnings - MarketBeat
Omeros’ (OMER) Hold Rating Reiterated at Needham & Company LLC - Defense World
Barclays PLC Acquires 51,873 Shares of Omeros Co. (NASDAQ:OMER) - MarketBeat
Barclays PLC Has $376,000 Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Earns “Buy” Rating from D. Boral Capital - Defense World
Omeros Corporation Announces Statistical Sensitivity Analyses Results for Narsoplimab - Defense World
Needham & Company LLC Reaffirms Hold Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Up 5.5%Time to Buy? - MarketBeat
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - MarketBeat
Narsoplimab shows promise in reducing mortality for TA-TMA patients - MSN
Omeros Co. (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Personal Finance - Business Wire
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint - Business Wire
Jane Street Group LLC Has $231,000 Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
When the Price of (OMER) Talks, People Listen - Stock Traders Daily
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
United Rentals (URI-N) QuotePress Release - The Globe and Mail
Omeros (NASDAQ:OMER) Stock Price Down 3.1%Time to Sell? - MarketBeat
Geode Capital Management LLC Has $5.32 Million Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Acquired by Barclays PLC - Defense World
Omeros (NASDAQ:OMER) Trading Up 10.3%Time to Buy? - MarketBeat
Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat
State Street Corp Has $4.87 Million Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):